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Abstract 
Poly(ADP-ribose) polymerases were originally described as DNA repair enzymes. PARP-1, 
PARP-2 and PARP-3 can be activated by DNA damage and the resulting activation of these 
enzymes facilitate DNA repair, a prerequisite of successful aging. Through more fit DNA repair 
systems PARP activation helps to maintain genomic integrity, however, in parallel these 
enzymes limit metabolic fitness and make the organism more prone for metabolic diseases. In 
addition, several other pathways (e.g. proteostasis, nutrient sensing, stem cell proliferation or 
cellular communication), all contributing to aging, were shown to be PARP mediated. In this 
review we aim to summarize our current knowledge on the role of PARPs in aging. 
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 Ageing, ageing-related pathologies  
With increases in lifespan, Western countries face an ever-growing number of aging 
people and growing number of ageing-related diseases. Aging is a natural process that is 
characterized by genomic instability, telomere attrition, epigenetic alterations, loss of 
proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, stem cell exhaustion, 
cellular senescence and altered intercellular communication [1]. On the course of ageing the 
prevalence of certain diseases increase as compared to the young(er) or mixed-age population 
such as metabolic diseases (type II. diabetes, obesity), certain malignancies, macular 
degeneration, osteoporosis, hearing loss - just to list a few. It is evident that identifying 
molecular targets that improve healthspan or the quality of life during ageing has obvious 
advantages for the society. 
Poly(ADP-ribose) polymerases (PARPs) were originally described as DNA repair proteins 
and in the late ‘90s Muiras and Bürkle [2] have shown that in centenarians in comparison to 
the average population have higher PARP activity in leukocytes suggesting that higher PARP 
activity is associated with successful aging. In the past years our understating of the 
relationship between PARP activity and aging has greatly improved and in this review we try 
to provide a comprehensive picture of the role of PARPs in ageing. 
 
The enzymology of poly(ADP-ribosyl)ation 
Poly(ADP-ribose) polymerases (PARPs) form a family of 17 in humans that share the same 
catalytic domain. PARPs are multidomain proteins contain additional domains – among others 
– domains for protein-protein interactions (e.g. 3rd zinc finger in PARP-1, BRCT domain, 
ankyrin repeats, etc., macrodomains for binding or cleavage of ADP-ribose, DNA/RNA binding 
domains (zinc finger or SAP domain) and nuclear or nucleolar localization signals [3, 4]. 
Poly(ADP-ribosyl)ation (PARylation) is an evolutionarily conserved biochemical process. 
Activated PARP-1 binds and cleaves NAD+ to ADP-ribose and nicotinamide (NAM) then binds 
ADP-ribose to glutamate, aspartate side chains [3]. To the first ADP-ribose moiety the enzyme 
can subsequently join new ADP-ribose units forming large, branched polymers counting up to 
200 individual ADP-ribose residues [3]. To date PARP-1, PARP-2 and tankyrases (TNK) are 
known to perform PARylation, the rest of the family performs oligo- or mono-ADP-ribosylation 
(inefficient or no elongation), can be inactive (mutation of catalytic amino acids) or its activity 
had not been characterized [5]. It must be noted that single ADPR units can be further 
elongated by PARPs capable of performing PARylation [6] 85-90% of the basal and DNA 
break-triggered PARP activity is covered by PARP-1, PARP-2 is responsible for the remaining 
10-15%, while the activity conferred by the rest of the family is negligible as compared to the 
total activity [5]. PARP-1, PARP-2 and PARP-3 are activated by DNA strand breaks, however 
different posttranslational modification may also modulate the activity of PARPs (for review 
see [7, 8]). 
PAR molecules can be joined onto PARP-1 or PARP-2 (autoPARylation) or onto other 
acceptor molecules (transPARylation). AutoPARylation inhibits PARP-1 activation and 
therefore inhibit PARP-1 overactivation, while removing PAR reactivates PARP-1 [5]. The PAR 
polymer is rapidly degraded in cells to ADPR. There are several enzymes capable of degrading 
PAR, such as poly(ADP-ribose) glycohydrolase (PARG) ADP-ribosyl-acceptor hydrolase 3 
(ARH3), ADP-ribosyl lyase and macrodomain-containing proteins [8]. Poly(ADP-ribose) 
glycohydrolase (PARG) removes PAR reverting and reactivating PARP-1. ADPR can be 
further fragmented to AMP by Nucleoside Diphosphate Linked to X (NUDIX) 
pyrophosphatases; increases in cellular AMP has pivotal role in mitochondrial deterioration 
inflicted by PARP activation [8]. 
PARPs are involved in a plethora of biological processes, hereby – due to space limitations 
- we refer the reader to reviews [4, 9]. 
 
Primary events of aging 
Genomic instability and telomere attrition 
Accumulating genetic damage during aging is unavoidable as genomic material is 
continuously challenged by exogenous (physical, chemical and biological) and endogenous 
(replication errors, hydrolytic reactions and oxidative damage) factors [10]. In order to maintain 
genetic integrity, a vast repertoire of DNA repair mechanisms stand ready to prevent DNA 
damage and accumulation of these lesions over time. It seems more likely that genomic 
instability during aging is rather a consequence of declined or impaired repair functions [10]. 
Should repair mechanisms fail, cells undergo apoptosis or suffer senescence as a tumor 
suppression mechanism.  
Many DNA repair mechanisms, counteracting the above-detailed changes, are PARP-
dependent processes. PARP-1, PARP-2 and PARP-3 were shown to be activated by DNA 
strand breaks [11]. PARPs have role in nucleotide excision repair to attack bulky adducts, base 
excision repair processes to counteract base modifications and in the repair of single and 
double strand breaks (both non-homologous end joining and homologous repair) and to 
maintain genomic integrity [11]. The deletion or pharmacological inhibition of PARP-1, PARP-
2 or PARP-3 does not lead to spontaneous genomic instability [11, 12], however, under 
genotoxic stress the loss of PARPs does lead to genomic instability [11]. In line with these 
observations, the simultaneous deletion of PARP-1 and PARP-2 or PARPs and other DNA 
repair enzymes lead to embryonic lethality that is characterized by the accumulation of DNA 
damage [11].  
There are specific regions of the genome that seem to be more prone to DNA damage. 
Telomeres, affected especially by age related shortening, are among these regions [13]. In 
somatic human cells, telomeres shorten with every round of replication and cells are triggered 
into replicative senescence once telomeres shorten to a critical length [13]. Telomeres can be 
rebuilt by the enzyme telomerase that has cofactors, such as telomeric repeat binding factor 1 
and 2 (TRF1 and TRF2, respectively) [13]. 
PARP-1, TNK1 and TNK2 are involved in telomere maintenance through different 
mechanisms. TNKs interact with TRF1 (but not TRF2) and both are localized together near the 
physical ends of metaphase chromosomes, implying TNKs as a components of the human 
telomeric complex [14]. TNKs have intrinsic PARP activity towards at least two substrates 
(TRF1 and themselves) [14] resulting in decreased binding of TRF1 to telomeres and induces 
proteasome-mediated degradation of TRF1, hence TRF1 is a negative regulator of telomere 
length [15]. In addition to TNKs, PARP-1 is also involved in telomere maintenance, wherein 
PARP-1 is a negative regulator of TRF2 [16]. Indeed, the absence of PARP-1 did lead to 
dramatically shortened telomeres in PARP-1-/- mice and cells [17, 18] and in such cells 
chromosomes are prone to end-to-end fusions [19].  
Muiras and Bürkle [2, 20-22] has linked better DNA repair capabilities upon higher total 
PARP activity with prolonged lifespan. Indeed, in centenarians, who actually aged 
successfully, higher PARP-1 activity was detected as compared the average of population [2]. 
Indeed, a subsequent study by Mangerich and co-workers [23] showed that the overexpression 
of an extra copy of PARP-1 in mice reduced the incidence of several malignant diseases clearly 
validating the original observations of Muiras [2]. 
 
Epigenetic alterations and changes in gene expression 
Epigenetics has been defined as the inheritance of changes in gene function without any 
change in the DNA nucleotide sequence. A variety of epigenetic alterations including 
posttranslational histone modifications and chromatin remodeling could be associated to 
influence aging [24]. PARP-1, PARP-2 and TNK1 were shown to modulate chromatin structure, 
to mediate both condensation and decondensation events and hence play indispensable role 
in establishing facultative and constitutive heterochromatin (Barr body, centrosome, 
pericentrosome, telomere, inactivated sex chromosome during meiosis, inactive rRNA genes, 
etc.) [25]. Moreover, PARP-1 impacts on epigenetic marks by PARylating histones and 
chromatin remodeling enzymes such as KDM5B, ISWI, ALC1, DNMT-1, CTCF etc. (for review 
see [26]) or can rearrange nucleosome and linker histone binding  through which PARP-1 
influences transcription [26]. PARP-1 binds to 90% of the Pol II-transcribed genes and 
mediates around 3.5% of all transcribed RNAs [26]. Besides PARP-1, PARP-2, -7, -10, -14 
regulates gene expression [4]. It is not yet fully confirmed by experimental data, however it is 
likely that the modulation of epigenetic factors by PARPs could impact on aging. 
 
Loss of proteostasis 
Proteostasis means the maintenance of protein turnover and functional proteins in all 
cellular compartments. Different forms of stress have an impact on the cell proteome which 
uses a vast number of protein stabilization and refolding mechanisms (via heat-shock proteins) 
to maintain the functionality of affected proteins. If proteins can’t be rescued, the incorrectly 
folded structures are targeted for lysosomal or proteasomal degradation to avoid their 
accumulation and aggregation [1]. Dysfunctional proteostasis is associated with aging and age 
related diseases like Alzheimer’s or Parkinson’s disease [1]. 
Overloading the protein translation machinery leads to the production of misfolded 
proteins that declutches a signaling mechanism called ER stress that slows down protein 
synthesis to enable cells to cope with misfolded, dysfunctional proteins. PARP-1 has regulatory 
role in translation [27] , moreover, PARP-1 has a role in ER-stress signaling [28]. 
Upon oxidative stress the 20S proteasome in the nucleus is rapidly activated in a PARP-
1 and PARylation-dependent fashion [29-32] that is closely linked to reduced rate of aging, 
increased proliferative capacity and tumor growth [33, 34]. In contrast to that, genetic or 
pharmacological inhibition of PARP-1 reduce proteolytic activity and induce senescence [35-
38]. 
Proteostasis is not limited to the removal of damaged proteins, but to the preservation of 
the balance between the protein content or protein composition between cellular organelles 
such as the balance between mitochondrial and nuclear proteins [39]. The regulatory circuit 
balancing between mitochondrial and nuclear protein pools is comprised of two arches. Energy 
stress sensor pathways (e.g. SIRT1, AMPK, etc.) help in translating shortcomings in cellular 
energetics into nuclear transcription programs that then upregulate mitochondrial energy 
production. The other arch is called retrograde signaling translating mitochondrial dysfunction 
(e.g. decreased expression or function of complex I) into nuclear transcriptional programs that 
can restore mitochondrial oxidation [39]. The activation of PARP-1 had been shown to 
influence mitonuclear protein balance through modulating SIRT1 activity [40]. 
 
Mitochondrial dysfunction 
Mitochondrial oxidation capacity deteriorates on the course of aging [1]. The negative 
effect of PARP-1 on mitochondrial activity was described in 1998 by Virág and co-workers [41]. 
PARP-1 overactivation blunts mitochondrial activity through several parallel pathways (for 
comprehensive review see [8, 42]): 1) inhibition of mitotropic transcription factors (e.g. SIRT1) 
[5, 43], 2) induction of transcription factors that suppress mitochondrial activity (e.g. HIFs) [44, 
45], 3) inhibiting mitochondrial membrane and membrane-associated enzymes (e.g. ANT, the 
hexokinase-ANT complex) by cytosolic PAR polymers [8, 46, 47], 4) impairs mitophagy and 
nuclear-mitochondrial protein balance [40, 48]. 
In contrast, the deletion or pharmacological inhibition of PARP-1 or PARP-2 enhances 
mitochondrial activity through inducing SIRT1 activity by enhancing cellular NAD+ levels or by 
inducing SIRT1 expression, respectively [5, 40]. Enhanced SIRT1 activity leads to the 
deacetylation of mitotropic transcription factors, such as FOXO1 or PGC-1α that induce 
transcription programs that support mitochondrial oxidative metabolism [5, 40]. PARPs interact 
with energy sensor (e.g. AMPK, NRFs, SIRT3 – for review see [8]), however, the involvement 
of these pathways in PARP-mediated changes in mitochondrial activity is poorly characterized.  
The balance between SIRT1 and PARP-1 has central role in setting the rate of 
mitochondrial oxidative metabolism. Both enzyme use a common substrate, NAD+ and can 
limit each other’s activity [5]. Several elegant studies from Braidy and co-workers (e.g. [49, 50]) 
have shown that the activity of PARP-1 enhances upon aging that reduces cellular NAD+ levels 
and consequently SIRT1 activity that blunts mitochondrial oxidation. Importantly, mitochondrial 
biogenesis – most probably in the skeletal muscle – upon the deletion of PARP-1 or PARP-2 
protect against type II. diabetes that is a classical aging-related metabolic disease [12]. In line 
with these findings the overexpression of PARP-1 in mice leads to type II. diabetes [23]. There 
are other PARPs with metabolic properties [12] suggesting that these enzymes may also 
participate in the metabolic rearrangements in aging. 
 
Deregulated nutrient sensing 
Nutrient availability defines the balance between anabolism and catabolism, moreover it 
is involved in the regulation of key aging-related processes, such as autophagy, cell divisions, 
hormonal signaling, diurnal rhythms, calorie restriction, etc. The systems that are involved in 
nutrient sensing are often referred as energy (stress) sensor pathways [51] and involve – 
among others – the AMPK-mTOR system, nuclear receptors or hormonal signaling. These 
sensor systems can be pharmacologically modulated to mimic dietary changes that modulate 
lifespan and healthspan (e.g. calorie restriction) [51]. 
The deletion of PARP-1 in mice led to perturbed diurnal rhythm and increased food uptake 
and negative energy balance [12] suggesting dysfunction of the central (hypothalamic) 
circadian regulation. Although direct molecular proofs are missing for the defects of central 
regulation, hepatic (i.e. peripheral) circadian oscillations are perturbed upon the 
pharmacological inhibition or the deletion of PARP-1 due to the absence of the PARylation of 
CLOCK protein and the consequent dysregulation of the CLOCK-BMAL/PER-CRY circuitry 
[52]. 
PARP activity responds to nutrient availability, in skeletal muscle autoPARylation and 
protein level of PARP-1 increased upon feeding mice with hypercaloric high fat diet, while 
fasting sharply reduced PARP-1 activity [12]. As an extension to that, several nutrient sensor 
pathways were shown to be mediated by PARP-1. PARP-1 influences the phophatidil-inositol-
3 kinase (PI3K)-Akt and glucagon-like peptide (GLP)-1 pathway through which PARP-1 
mediates insulin (and probably growth factor) signaling [53-56]. There are numerous examples 
where PARPs interact with nuclear receptors and hence mediate sensing intra or extracellular 
lipid levels [8]. The impact of the interactions between PARP-1 and energy sensors (AMPK, 
mTORC1, NRFs, HIFs, SIRTs - see also the previous chapter and [4, 8]) on nutrient sensing 
had not been assessed. Taken together, the current data suggest that PARP-1 influences both 
central and peripheral sensing of lipids, glucose and amino acids. Little is known about PARPs 
other than PARP-1, primarily due to the lack of dedicated in vivo studies, however, PARP-2 is 
known to interplay with beta cell function and certain nuclear receptors [57], while tankyrases 
impact on beta cell function and feeding [58]. 
 
Integrative events of ageing 
Stem cell exhaustion 
With the progress of aging it is very common for different tissues to have an impaired 
regenerative ability due to compromised stem cell renewal capacity [1]. Importantly, PARP-1 
and PARP-7 define in stem cells whether cells undergo terminal differentiation or renewal [59]. 
PARP-2 activity had been also linked with sustaining hematopoietic stem cell (HSC) production 
[60, 61] or thymopoiesis [62].The application of PARP inhibitors, mostly through inhibiting 
PARP-1, influence the differentiation of bone marrow-derived cells, neurons, spermatocytes, 
skeletal muscle, osteoblasts and adipocytes [4]. Although it is very likely that PARP activation 
may alter the renewing capacity of stem cells, yet, direct evidences are missing. 
 
Cellular senescence 
A hallmark of cellular senescence is the slowdown or complete stop of cell cycle [1]. 
PARylation levels change on the course of the cell cycle [4], being the highest in G2 and S 
phase, while the lowest in G1  that is probably linked to DNA repair. The degradation of PAR 
or TNK1 silencing leads to a pre-anaphase block, PARP-1 is required for primase activity and 
replication-coupled repair and its absence leads to G2/M arrest when genotoxic stress is 
present. PARP-6 is necessary to leave the S-phase, while PARP-3 regulates the G1 to S phase 
progression. Taken together, PARPs are required for sustaining the progression of cell cycle. 
 
Compromised intercellular communication 
There are several modalities of communication between cells of an organism, the 
hormones of the endocrine system, cytokines or chemokines, etc. Although our knowledge is 
limited on the endocrine functions of PARPs, it is clear that PARPs are involved in the function 
of pancreatic beta cells [12] or different peptide hormones, among them several adipokines 
(Fig. 1. and [63, 64]). The involvement of PARP-1 in the age related changes in insulin 
secretion and the consequent appearance of type II. diabetes was suggested by Mangerich et 
al. [23], pointing towards the possibility of other PARP-mediated, age-related endocrine 
changes. 
Ageing-related changes in the inflammatory system involve inflammaging. In 
inflammaging the normal function of the immune system is compromised: on the one hand, 
low grade inflammation commences in tissues (e.g. white adipose tissue) that on the long run 
deteriorates the function of these tissues, while on the other, the elimination of pathogens is 
limited. PARP-1 and PARP-2 control the expression of a plethora of chemokines, cytokines, 
inducible nitric oxide synthase (iNOS) and polyunsaturated fatty acids and exert pro-
inflammatory roles in Th1 and Th2-mediated pathologies [65, 66]. It is tempting to speculate 
that ageing-related enhancement of PARP activity may feed-forward the low grade 
inflammation that accompanies inflammaging. Furthermore, PARP-1 and PARP-2 plays role 
in free radical-induced cell death that often accompany inflammation (also called a bystander 
effect) [4, 42] adding another modality to the pro-aging role for these enzymes. It must be noted 
that there are anti-inflammatory PARPs as well (e.g. tankyrases), however the role of these 
PARPs in aging is completely unknown. Finally, PARP-1 regulates endothelial NOS function 
and the production of oxygen-centered reactive species (e.g. mitochondrial uncoupling) 
through which it impacts on the function of gaseotransmitters [67]. 
 
Conclusions 
Since the first pioneering observation, where higher PARP-1 expression was found in 
centenarians [2] that was linked to improved DNA damage sensing and more efficient repair, 
a way more complex picture was obtained on the role of PARPs in aging. PARP-1 and, to a 
smaller extent, PARP-2 are key factors in aging-related diseases (neurodegenerative 
diseases, metabolic diseases, etc.) [4], finally the competing nature of the anti-aging action of 
PARP-1 and PARP-2 (maintaining DNA integrity) and the pro-aging actions (increased 
susceptibility to metabolic diseases) was discovered [23] (see graphical abstract). In other 
words, PARP activation is a double-edged sword in aging, while enhanced PARP activity 
ensures DNA integrity, PARP activation at the same time makes the organism more 
susceptible to metabolic diseases [23]. Recent advances uncovered novel, PARP-mediated 
pathways (loss of proteostasis, changes in nutrient sensing, stem cell exhaustion or the 
deregulation of intercellular communication) that may contribute to aging, warranting further 
research in these directions. It is important to underline that PARP activation was detected in 
several aging-related diseases: neurodegenerative diseases such as Alzheimer’s disease, 
type II. diabetes and other metabolic diseases, ocular degenerative diseases [4] that clearly 
underlines the role of PARPs in the definition of healthspan, however, according to our current 
knowledge, the action of PARPs on lifespan is more limited. 
There are several questions that remain still open. The studies that define the impact of 
PARPs on lifespan are missing similarly to the studies aiming to understand the role of minor 
PARP isoforms in aging. Finally, the applicability of the administration of NAD+ or NAD+ 
precursors and other NAD+-dependent enzymes (e.g. sirtuins, such as SIRT6) still needs to be 
better elucidated. 
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Legends to Figures 
 
Figure 1. PARP-2 modulates the expression of adipokines. 
The expression of the above adipokines were determined in the white adipose tissue of PARP-
2+/+ and PARP-2-/- male mice (n=6/7, 6 months of age). Error bars represent SEM.  
 
